Kenvue (NYSE:KVUE), the consumer healthcare spin-off from Johnson & Johnson, has experienced a significant decline in its stock price in recent months.

Not long after President Trump made his statement, Kenvue and Johnson & Johnson got into another complicated legal mess when the Republican state of Texas sued them. The complaint says that the companies didn’t tell people about the possible risks of taking acetaminophen while pregnant.

The major stock indexes were mostly higher in premarket trading on Monday ahead of another busy week of quarterly earnings reports, as well as key private sector employment data.

Kenvue faces declining sales and high debt post-spin-off. Read why a dividend cut may be imminent and why KVUE stock is a Sell.